Back to News
Market Impact: 0.18
5 Biotech Stocks Worth Adding to Your Portfolio Now
Source: zacks.com
Healthcare & BiotechCompany FundamentalsAnalyst InsightsCorporate Guidance & Outlook
The article argues that new drug approvals and encouraging pipeline progress should keep momentum in the biotech/genetics space despite an uncertain macro backdrop. It highlights that a strong set of companies/portfolios—HALO, RGEN, IOVA, ARQT, and PGEN—are positioned to benefit from solid pipeline progress in a volatile sector.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
ARQT0.25
HALO0.25
IOVA0.25
PGEN0.25
RGEN0.25
More News
- AI rapidly improving, could vastly boost U.S. GDP, Anthropic's Clark tells policymakers
- ‘How many canaries have we killed in the coal mine?’ — Wall Street debates if the latest AI bubble warnings are another head fake or the real thing
- Bending Spoons wants to revive software castoffs. Berkshire is backing the plan
- Semiconductor market to remain solid ‘at least through next year,’ South Korea finance minister says
- Ericsson’s organic sales rise 7% as it merges its two Asian units
- TSMC posts a sixth straight record profit but turns cautious on 2027
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Financial Research Benchmarks: What the Scores Mean
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper